Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Von Hoff

Showing results (11-20 of 80) with videos related to

Pageof 8
Sort By:
Investigational New Drugs|November 11, 2008
Blackberry-induced hand-foot skin reaction to sunitinibSusan L Boone, Gayle Jameson, Daniel Von Hoff, et al.
Gastroenterology|April 29, 2023
Intratumoral Malasseziaglobosa Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal AdenocarcinomaKeisuke Okuno, Masanori Tokunaga, Daniel Von Hoff, et al.
Frontiers in Oncology|April 26, 2021
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma CellsLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Journal of Cellular Physiology|January 18, 2020
GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacyLaurence Booth, Jane L Roberts, Cameron West, et al.
World Journal of Gastroenterology|December 21, 2017
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumorsAhmad Al-Hader, Rami N Al-Rohil, Haiyong Han, et al.
Journal of Clinical Pharmacology|January 11, 2017
A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and TipiracilCarlos R Becerra, Kenichiro Yoshida, Hirokazu Mizuguchi, et al.
Frontiers in Oncology|September 7, 2021
GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 ProteinsLaurence Booth, Cameron West, Robert P Moore, et al.
Cellular Signalling|January 9, 2020
Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]Paul Dent, Laurence Booth, Andrew Poklepovic, et al.
Oncotarget|January 17, 2022
GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cellsLaurence Booth, Cameron West, Robert P Moore, et al.
Oncotarget|February 9, 2022
GZ17-6.02 and axitinib interact to kill renal carcinoma cellsLaurence Booth, Cameron West, Robert P Moore, et al.
Pageof 8

Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Investigational New Drugs|November 11, 2008
Blackberry-induced hand-foot skin reaction to sunitinibSusan L Boone, Gayle Jameson, Daniel Von Hoff, et al.
Gastroenterology|April 29, 2023
Intratumoral Malasseziaglobosa Levels Predict Survival and Therapeutic Response to Adjuvant Chemotherapy in Patients With Pancreatic Ductal AdenocarcinomaKeisuke Okuno, Masanori Tokunaga, Daniel Von Hoff, et al.
Frontiers in Oncology|April 26, 2021
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma CellsLaurence Booth, Cameron West, Daniel Von Hoff, et al.
Journal of Cellular Physiology|January 18, 2020
GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacyLaurence Booth, Jane L Roberts, Cameron West, et al.
World Journal of Gastroenterology|December 21, 2017
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumorsAhmad Al-Hader, Rami N Al-Rohil, Haiyong Han, et al.
Journal of Clinical Pharmacology|January 11, 2017
A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and TipiracilCarlos R Becerra, Kenichiro Yoshida, Hirokazu Mizuguchi, et al.
Frontiers in Oncology|September 7, 2021
GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 ProteinsLaurence Booth, Cameron West, Robert P Moore, et al.
Cellular Signalling|January 9, 2020
Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate]Paul Dent, Laurence Booth, Andrew Poklepovic, et al.
Oncotarget|January 17, 2022
GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cellsLaurence Booth, Cameron West, Robert P Moore, et al.
Oncotarget|February 9, 2022
GZ17-6.02 and axitinib interact to kill renal carcinoma cellsLaurence Booth, Cameron West, Robert P Moore, et al.
Pageof 8